- 3448

[] Institution:Study Staff Contact – [3448] Trial:An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

It seems we can’t find what you’re looking for. Perhaps searching can help.